Literature DB >> 2443417

Epitope-specific immune responses to rotavirus vaccination.

R D Shaw1, K J Fong, G A Losonsky, M M Levine, Y Maldonado, R Yolken, J Flores, A Z Kapikian, P T Vo, H B Greenberg.   

Abstract

Rotavirus gastroenteritis is a leading cause of infant mortality in developing countries and an important cause of morbidity in children under 2 yr of age in the United States. Vaccine programs have evaluated animal rotavirus strains that are attenuated in humans but antigenically similar to some human strains. Whether a single vaccine strain can elicit protective immunity in humans to rotaviruses of the same or different serotypes is an important question in determining vaccine efficacy. We used characterized serotype-specific monoclonal antibodies directed at VP7 in a competitive solid-phase immunoassay to measure epitope-specific immune responses to serotypes 1, 2, and 3 in sera of children who received a candidate serotype-3 rotavirus vaccine. Antibodies to serotype 3 were detected in 72% of sera samples, and to serotype 1 and 2 in only 11% each. Also, a VP3-specific monoclonal antibody which neutralizes three serotypically distinct strains of rotavirus was used to detect the presence of similar antibodies in 56% of the test sera. This finding suggests a mechanism of heterotypic immunity.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2443417     DOI: 10.1016/0016-5085(87)90555-5

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  27 in total

1.  Specific interactions between rotavirus outer capsid proteins VP4 and VP7 determine expression of a cross-reactive, neutralizing VP4-specific epitope.

Authors:  D Y Chen; M K Estes; R F Ramig
Journal:  J Virol       Date:  1992-01       Impact factor: 5.103

2.  Comparisons of rotavirus VP7-typing monoclonal antibodies by competition binding assay.

Authors:  P Raj; D O Matson; B S Coulson; R F Bishop; K Taniguchi; S Urasawa; H B Greenberg; M K Estes
Journal:  J Clin Microbiol       Date:  1992-03       Impact factor: 5.948

3.  Homotypic and heterotypic serological responses to rotavirus neutralization epitopes in immunologically naive and experienced animals.

Authors:  D R Snodgrass; T A Fitzgerald; I Campbell; G F Browning; F M Scott; Y Hoshino; R C Davies
Journal:  J Clin Microbiol       Date:  1991-11       Impact factor: 5.948

4.  Antibodies to the trypsin cleavage peptide VP8 neutralize rotavirus by inhibiting binding of virions to target cells in culture.

Authors:  F M Ruggeri; H B Greenberg
Journal:  J Virol       Date:  1991-05       Impact factor: 5.103

5.  Serum-neutralizing antibody to VP4 and VP7 proteins in infants following vaccination with WC3 bovine rotavirus.

Authors:  R L Ward; D R Knowlton; H B Greenberg; G M Schiff; D I Bernstein
Journal:  J Virol       Date:  1990-06       Impact factor: 5.103

6.  DNA amplification-restricted transcription-translation: rapid analysis of rhesus rotavirus neutralization sites.

Authors:  E R Mackow; M Y Yamanaka; M N Dang; H B Greenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1990-01       Impact factor: 11.205

Review 7.  Rotavirus gene structure and function.

Authors:  M K Estes; J Cohen
Journal:  Microbiol Rev       Date:  1989-12

8.  The rhesus rotavirus gene encoding protein VP3: location of amino acids involved in homologous and heterologous rotavirus neutralization and identification of a putative fusion region.

Authors:  E R Mackow; R D Shaw; S M Matsui; P T Vo; M N Dang; H B Greenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1988-02       Impact factor: 11.205

9.  Comparison of immunoglobulin A (IgA), IgG, and IgM enzyme-linked immunosorbent assays, plaque reduction neutralization assay, and complement fixation in detecting seroresponses to rotavirus vaccine candidates.

Authors:  K Midthun; L Z Pang; J Flores; A Z Kapikian
Journal:  J Clin Microbiol       Date:  1989-12       Impact factor: 5.948

10.  Resistance to rotavirus infection in adult volunteers challenged with a virulent G1P1A[8] virus correlated with serum immunoglobulin G antibodies to homotypic viral proteins 7 and 4.

Authors:  Lijuan Yuan; Shinjiro Honma; Inyoung Kim; Albert Z Kapikian; Yasutaka Hoshino
Journal:  J Infect Dis       Date:  2009-11-01       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.